Trial Profile
A Randomized, Double-blind, Placebo Controlled, Parallel Group, Proof of Concept Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of QGE031 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Oct 2023
Price :
$35
*
At a glance
- Drugs Ligelizumab (Primary) ; Ciclosporin
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 01 Oct 2023 Results assessing the safety and efficacy of ligelizumab versus placebo in adult patients with moderate-to-severe Atopic Dermatitis, published in the Journal of Investigative Dermatology.
- 31 Oct 2014 New trial record